Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study

Trial Profile

Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NADIM
  • Most Recent Events

    • 12 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2018 Preliminary results presented at the 19th World Conference on Lung Cancer
    • 05 Jun 2018 Results (n=30) assessing preliminary data on patients that completed 3 cycles and underwent surgical assessment, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top